Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Non Operating Income (2016 - 2025)

United Therapeutics' Non Operating Income history spans 17 years, with the latest figure at $87.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 125.0% year-over-year to $87.3 million; the TTM value through Dec 2025 reached $221.4 million, up 36.67%, while the annual FY2025 figure was $221.4 million, 36.67% up from the prior year.
  • Non Operating Income for Q4 2025 was $87.3 million at United Therapeutics, down from $138.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $138.5 million in Q3 2025 and bottomed at -$68.1 million in Q4 2023.
  • The 5-year median for Non Operating Income is $13.8 million (2022), against an average of $18.5 million.
  • The largest YoY upside for Non Operating Income was 1885.71% in 2021 against a maximum downside of 24200.0% in 2021.
  • A 5-year view of Non Operating Income shows it stood at -$29.3 million in 2021, then soared by 119.8% to $5.8 million in 2022, then plummeted by 1274.14% to -$68.1 million in 2023, then soared by 156.98% to $38.8 million in 2024, then surged by 125.0% to $87.3 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Non Operating Income are $87.3 million (Q4 2025), $138.5 million (Q3 2025), and -$100000.0 (Q2 2025).